45LOW

PEB

PACIFIC ED FPO NZX [PEB]
Healthcare · ASX Small Cap
$0.1700 -5.6%

Updated 2026-03-02 · Scores refresh every scan

Appeared in 2 consecutive scans→ Score +6First seen: 2026-02-25

Score Breakdown

Technical44
Catalyst43
Sentiment50
Fundamental36
Momentum62
Risk Gate37

Active Signals

Bullish Signals

  • RSI approaching oversold
  • Sharp 5-day decline (-17.1%)
  • Above 200-day MA (long-term uptrend)
  • Low cash runway (3 quarters) - dilution risk
  • Moderate P/S ratio (10.1x)
  • Revenue in sharp decline (-40%)
  • CANSLIM I: Institutional ownership (34%)
  • Strong 12-1 momentum (+100%)
  • Days to cover very high (11.1)
  • ASX200 bullish (+1.5% 5d)
  • RBA cutting (+2pts)

Risk Signals

  • MACD momentum weakening
  • Piotroski F-Score weak (3/9)
  • Deeply negative margins (-189%)
  • Insufficient sentiment data (defaulting to neutral)
  • Neutral/mixed sentiment
  • Revenue momentum declining (-40%)

Recent Catalysts

NONE Panel Expresses Support for Urine-Based Biomarkers
NONE Change in substantial holding
NONE Medicare Contractor Novitas Schedules Expert Panel
NEGATIVE Trading Halt
Announcement tone +3pts

Recent ASX Announcements

2026-02-22 Panel Expresses Support for Urine-Based Biomarkers PRICE SENSITIVE
2026-02-19 Trading Halt PRICE SENSITIVE
2026-02-13 Change in substantial holding
2026-02-08 Medicare Contractor Novitas Schedules Expert Panel
2026-01-30 Change in substantial holding

Key Metrics

$184.0M
Market Cap
96K
Avg Volume
1.9x
Vol Ratio
$0.07 — $0.22
52-Week Range
0.1%
Short Interest
N/A
Cash Runway
-102.3%
ROE
-189.4%
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandneutralFloat: 86%
LLeader vs LaggardpassRS: 6
IInstitutional SponsorshippassInst: 34%
MMarket DirectionpassBullish

Sector: Healthcare

Ranked #101 of 119 · Sector avg: 51

View all Healthcare signals →
Related Tickers
AVE 66CUV 64NEU 60HLS 59IMM 59

Sign up free to unlock PEB analysis

Score breakdowns, signals, catalysts, and full analysis for 2,200+ ASX small caps. All features free during early access.

No credit card required. Unsubscribe anytime.
Already have access? Log in